Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05710211
Recruiting Not applicable

Clonal Architecture of ASXL1-mutated Myelofibrosis

NCT05710211 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Angers
Phase
Not applicable
Started
2023-04-24
Last updated
2026-03-09

Condition(s) studied

Myelofibrosis

Investigational drug(s) / intervention(s)

Clonal architecture determination

Clonal architecture determination: Biological: * Determination of clonal architecture by sorting of circulating CD34 positive cells followed by cell culture and colony genotyping and/or single-cell DNA-sequencing * Secondary outcome: transcriptomic study by RNA-sequencing

Study summary

Prospective study to decipher the clonal architecture of ASXL1-mutated primary and secondary myelofibrosis and its impact on prognosis

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults (age ≥18 years), * Affiliated to the national social security system, * ASXL1 mutated primary or secondary myelofibrosis, * Signed the consent to participate in the study, * Included, or consenting to be included, in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM). Exclusion Criteria: * Patient with another active hematological disease or cancer at the time of diagnosis, * Person subject to legal protection scheme or incapable of giving consent.

Primary outcome measure(s)

  • Identify subgroups of ASXL1-mutated myelofibrosis based on clonal architecture data — 24 months
    The clonal architecture is defined by the number of mutations (numerical), the order of acquisition of the mutations (categorial, pre/post/separated), the mutational branching (categorial, yes/no), the presence of distinct clones (categorial, yes/no) and the transition towards homozygosity of each clone (categorial, yes/no). All parameters of clonal architecture will be analyzed together using a multivariate classification (Factor Analysis for Mixed Data) followed by a clustering which allow us to identify homogeneous cluster of patients.

Trial sites (13)

FacilityCityRegionStatus
CHU Angers Angers France Recruiting
CHRU Brest Brest France Not Yet Recruiting
CH Cholet Cholet France Not Yet Recruiting
CHU Henri MONDOR Créteil France Recruiting
Institut Paoli Calmettes Marseille France Recruiting
CHU Nantes Nantes France Not Yet Recruiting
AP-HP Hôpital Saint Louis Paris France Not Yet Recruiting
Hôpital Bicêtre Paris France Recruiting
CHU de Bordeaux Pessac France Recruiting
CHU Lyon Pierre-Bénite France Recruiting
CH de Cornouaille Quimper France Not Yet Recruiting
CHRU Tours - Hôpital Bretonneau Tours France Recruiting
CH de Vannes Vannes France Not Yet Recruiting

More University Hospital, Angers trials in France

Postoperative Analgesia Using a Perineural Catheter Versus a Single Nerve Block in Rearfoot Surgery Recruiting
Impact of Prevention of Safe Sleeping and Unexpected Infant Death Starting soon
Assessment of the Mental State of Parents of Premature Children and Impact on Neurodevelopment of the Child Active, not recruiting
Human Seminal Plasma Allergy: Quality of Life Starting soon
AttachMent Preterm in the Loire Infant Follow-up Team Recruiting

Other trials for the same condition

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) Active, not recruiting
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions Active, not recruiting
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) Active, not recruiting
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib Recruiting
A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05710211 on ClinicalTrials.gov ↗ ← All trials in France